/** Title: Dhansa Labs FY26: Steady agrochemicals, Atrazine expansion, and a bigger bet on CBG */

Dhansa Labs FY26: Steady agrochemicals, Atrazine expansion, and a bigger bet on CBG

Dhansa Labs Limited ended FY26 with moderate growth in its core agrochemicals business and a clear shift in narrative toward capacity expansion and diversification. Revenue from operations rose to INR 14,153.72 lakhs in FY26, compared with INR 13,126.99 lakhs in FY25. EBITDA was reported at INR 1,221.80 lakhs, and profit after tax was INR 552.26 lakhs.

Management positioned FY26 as a year of operational discipline and groundwork for the next phase. The company’s stated ambition is to become larger and more diversified, supported by a brownfield expansion for Atrazine manufacturing at its existing Rajasthan facility, and a greenfield move into compressed biogas through a wholly owned subsidiary.

Revenue mix: still an agrochemicals-led story

Dhansa Labs operates in two operating segments in the presentation: Agro Chemical Products and Home Hygiene Products. But the mix remains overwhelmingly agro-driven.

In the product-wise revenue bifurcation disclosed for FY26, agro chemical products accounted for 96.67% of revenue, while home hygiene and other products contributed 3.33%. This split has remained largely consistent over FY24 to FY26, indicating that the hygiene portfolio is present but not yet a meaningful driver at the company level.

Geographically, domestic revenue dominated at 94.26% of total revenue, with exports at 5.74%. Export revenue in FY26 was shown only from Thailand at INR 811.97 lakhs. Domestic revenue was concentrated in a few states, with Delhi and Haryana together contributing more than 80% of domestic revenue as per the FY26 table.

Manufacturing and utilization: mixed picture across product lines

The company highlighted its state-of-the-art manufacturing facility and backward integration, along with ZLD compliance. Capacity utilization data in the presentation shows that utilization differs sharply by product family.

For 2,4-D, utilization in FY26 was shown at 69.37%. In contrast, Pretilachlor and Metribuzin utilization was 34.58% in FY26, after 24.08% in FY25. This suggests that the company has room to drive better throughput in at least part of its portfolio.

Management also spoke about entering smaller pack markets under both customer brands and its own brand, which is a typical lever to improve plant utilization and increase wallet share. However, the presentation does not quantify the size of the small-pack opportunity or timelines.

The near-term growth lever: Atrazine expansion

The most specific near-term growth project discussed was Atrazine. In the concall, management stated that the Atrazine project is planned with an estimated investment of about INR 30 crore. It is described as a brownfield expansion at the existing facility.

The company intends to start the project by August 2026 and expects it to stabilize by the end of the year. Management stated the project could contribute around INR 120 to 140 crore in annual revenue upon stabilization, and that in the first year of commencement it expects an initial revenue target of about INR 40 crore.

This is one of the clearer disclosures in the documents because it ties together capex, timeline, and a revenue potential figure. Asset turnover, margin impact, or return metrics were not disclosed.

Diversification: green energy and pellets

Dhansa Labs is also pushing into renewable energy through subsidiaries.

Dhansa Green Energy Private Limited is developing a 15 TPD compressed biogas project. In the concall, management stated the project cost exceeds INR 120 crore and is expected to commence commercial operations by July 2027. Management also stated that debt for the project has been finalized at about INR 85 crore, with the remaining equity contribution planned to come from warrants issued in August 2025.

A central part of the renewable platform is Napier grass cultivation in Bundi district, Rajasthan. Management stated plans to cultivate more than 350 acres of Napier grass to create a reliable feedstock ecosystem. The rationale given was long-term stability of feedstock costs and reduced dependence on availability of agro-waste such as spent wash or press mud, which is typically controlled by large sugar or ethanol producers. Management also mentioned potential carbon credit benefits.

The second subsidiary, Dhansa Biofuels Power Private Limited, is aimed at producing biomass pellets as a cleaner alternative to coal. In the Q&A, management stated biofuels capex would be approximately INR 120 crore, but also indicated that financial closure for pellets would be lined up after beginning construction for the CBG project.

What management guided for FY27

Management gave limited quantitative guidance. The key forward statement in the concall was an expectation of about 20% revenue growth in FY27, while noting that exact numbers are difficult to provide because capex is in progress.

On exports, management said it remains focused on expanding presence in high-potential geographies, specifically mentioning Australia, Latin America, and the United States. The documents do not quantify export targets.

Risks highlighted within the documents

Working capital emerged as a recurring theme. The presentation’s SWOT section explicitly lists high working capital as a weakness that constrained the ability to meet export demand.

In the concall, an investor questioned the jump in trade receivables and raised concerns about operating cash flow. Management attributed the receivables increase to export delays at ports and delayed payments due to disruptions linked to ongoing wars, and said it expects receivables to normalize, possibly in the first half of FY27.

Another area to watch is capital allocation. The company is discussing sizable capex across Atrazine, CBG, and pellets. While management emphasized prudent capital allocation, return metrics such as ROCE or payback for these projects were not provided.

Takeaways

Dhansa Labs remains primarily an agrochemicals business, with revenue still overwhelmingly dependent on agro chemical products and domestic customers. FY26 delivered growth in revenue and PAT versus FY25, and management is using the year to set up a more aggressive capex cycle.

The Atrazine project is positioned as a near-term growth driver with a defined capex and timeline. The larger strategic bet is renewable energy through the 15 TPD CBG project, with a stated commercial operation target of July 2027, supported by Napier cultivation for feedstock security. Execution, funding discipline, and working capital normalization will be the key variables that determine how smoothly this next phase plays out.